{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/shingles/prescribing-information/antiviral-drugs/","result":{"pageContext":{"chapter":{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs","depth":2,"htmlHeader":"<!-- begin field 051fa98f-1e8e-4372-93f1-5959d84b7b86 --><h2>Antiviral drugs</h2><!-- end field 051fa98f-1e8e-4372-93f1-5959d84b7b86 -->","summary":"","htmlStringContent":"<!-- begin item 5c6e411e-8575-4a91-87da-0bb229cc21fa --><!-- end item 5c6e411e-8575-4a91-87da-0bb229cc21fa -->","topic":{"id":"012e484d-8c14-5168-bb5d-e5acb7d4571a","topicId":"2969a8ac-cb7f-4569-be79-822e6009081a","topicName":"Shingles","slug":"shingles","lastRevised":"Last revised in October 2020","chapters":[{"id":"eeb1b918-6c05-5340-b348-ce2809516623","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8ad8b1b2-36bb-5262-ab5a-05763d6e4c7d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b1aed669-8481-5315-ab58-4bb18606e360","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8fef2c66-91dc-57c6-8cd3-4e4eff8d7727","slug":"changes","fullItemName":"Changes"},{"id":"ea603e45-ec07-5201-a182-ebef4c48ef6b","slug":"update","fullItemName":"Update"}]},{"id":"81feec28-1a5d-5a24-9c52-bee13821b03b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb672f83-c2bd-5dd7-9934-78f09729db48","slug":"goals","fullItemName":"Goals"},{"id":"2036bd3f-37bc-5cea-887d-55c3fc68c7cf","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cc04b460-a0d8-5e8d-b8d0-c044947b4bd6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ee3573cb-38d5-5d4c-9c9d-cd274242d964","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"52999d3b-9cce-59c5-b588-1f7ad7de33e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"40a91fd6-3c01-5713-85ad-0a5c4379eab9","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"04a0af22-814d-5b14-b28c-7916f1772a4d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"097dfec6-754a-54a8-9d96-44e1c5704248","slug":"definition","fullItemName":"Definition"},{"id":"f20034b1-ae3e-505b-ac16-3e11f2a6653e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e92f0243-b1ac-50d9-a31a-a07a4c61c5a7","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b6f8c581-b332-5d26-ba45-ccfb7189a387","slug":"complications","fullItemName":"Complications"},{"id":"012c8f32-e9cf-5897-a695-4c21cd28ae5d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"81f3feff-d640-5ee2-83fa-af1a4e8b586a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"56b89dcf-d466-50f3-a8a0-3a9477ef3362","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"01bc96b7-ea05-59b9-963a-16b2722b9367","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"acd9aec2-87d6-5084-bd3a-5c0b1d164ab4","fullItemName":"Management","slug":"management","subChapters":[{"id":"9872f447-6f59-502d-b6cb-a0fae6d2c085","slug":"management","fullItemName":"Scenario: Management"},{"id":"9ecdcc36-4fec-5b60-aa42-2032f2c406a4","slug":"prevention","fullItemName":"Scenario: Prevention"}]},{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4445c1da-4f7a-5f12-a909-0112bbd72453","slug":"antiviral-drugs","fullItemName":"Antiviral drugs"},{"id":"1223613b-f5a6-5da6-a311-275f5d6181b2","slug":"zostavax","fullItemName":"Zostavax"}]},{"id":"67979756-a00f-5f10-a93e-81509b35e1a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"625749c2-4e09-57ba-bdee-cd206d8b02d5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"377ce207-6229-5548-aef7-a637f176a94e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19ac0831-d4e2-52c3-b127-e78b1f26fb6f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d46d7aff-a113-50d5-afa1-3310aad844d7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d23205e9-41c9-5c70-a9f9-5ce3cfae633a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cf98894b-c083-59fd-8150-f390845960f1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a52b727c-ba28-5973-9e3c-e4882a883593","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"929d18e1-e1f0-5d08-8c55-d289b349a9fd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ba847fe0-ac93-5045-9073-6337cd9faffc","slug":"choice-of-antiviral-drug","fullItemName":"Choice of antiviral drug","depth":3,"htmlHeader":"<!-- begin field 7a1edfb6-395c-4562-bd1c-aad600e30461 --><h3>Which antiviral drug should I prescribe?</h3><!-- end field 7a1edfb6-395c-4562-bd1c-aad600e30461 -->","summary":"","htmlStringContent":"<!-- begin item 2d68d5e4-e86f-45ed-a177-aad600e30412 --><!-- begin field 8671511e-f6b4-4e94-803e-aad600e30461 --><ul><li><strong>Prescribe aciclovir, famciclovir, or valaciclovir, taking into account factors such as <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/#contraindications-cautions\">contraindications and cautions</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/#adverse-effects\">adverse effects</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/#drug-interactions\">drug interactions</a>, in addition to <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/#recommended-dosage\">dosing frequency</a> and acquisition cost.</strong><ul><li>Aciclovir, famciclovir, and valaciclovir are all licensed for the treatment of shingles in adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>].</li><li>Evidence suggests superior efficacy of oral valaciclovir and famciclovir over oral aciclovir for different outcomes. However, the evidence was not consistently reproduced [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">McDonald et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Cohen, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Werner, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">PHE, 2019b</a>]. Studies comparing the effects on cutaneous and pain end points between famciclovir and valaciclovir found that there are no differences in the efficacy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">BMJ, 2018</a>].</li></ul></li></ul><!-- end field 8671511e-f6b4-4e94-803e-aad600e30461 --><!-- end item 2d68d5e4-e86f-45ed-a177-aad600e30412 -->","subChapters":[]},{"id":"77cab051-91a9-5567-85a6-13f65dd4255d","slug":"recommended-dosage","fullItemName":"Recommended dosage","depth":3,"htmlHeader":"<!-- begin field 8ba7466a-b861-4b93-89c4-a6b9010a327f --><h3>What are the recommended dosages for oral aciclovir, famciclovir, and valaciclovir?</h3><!-- end field 8ba7466a-b861-4b93-89c4-a6b9010a327f -->","summary":"","htmlStringContent":"<!-- begin item 3ed44b8d-923b-4c87-a350-a6b9010a2fe9 --><!-- begin field 2ef6e44a-dacb-4ff8-b942-a6b9010a327f --><ul><li><strong>The recommended dosages are as follows:</strong><ul><li>For immunocompetent adults:<ul><li>Aciclovir: 800 mg five times a day for 7 days at 4-hourly intervals, omitting the night time dose. </li><li>Famciclovir: 500 mg three times a day for 7 days, <em>or </em>750 mg 1–2 times a day for 7 days.</li><li>Valaciclovir: 1000 mg three times a day for 7 days.</li></ul></li><li>For immunocompromised adults (if they are not systemically unwell and the rash is localized):<ul><li>Aciclovir: 800 mg five times a day for 7 days. Continue for 2 days after the lesions have crusted. </li><li>Famciclovir: 500 mg three times a day for 10 days. Continue for 2 days after the lesions have crusted.</li><li>Valaciclovir: 1000 mg three times a day for 7 days. Continue for 2 days after the lesions have crusted. </li></ul></li></ul></li><li><strong>In renal impairment:</strong><ul><li>For aciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>]:<ul><li>If estimated glomerular filtration rate (eGFR) is 10–25 mL/minute/1.73 m<sup>2</sup>, reduce the dosage to 800 mg every eight hours.</li><li>If eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, reduce the dosage to 800 mg every twelve hours.</li></ul></li><li>For famciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>]:<ul><li>If creatinine clearance (CrCl) is 40–59 mL/minute, reduce the dosage to 500 mg every twelve hours.</li><li>If CrCl is 20–39 mL/minute, reduce the dosage to 500 mg once a day.</li><li>If CrCl is less than 20 mL/minute, reduce the dosage to 250 mg once a day.</li></ul></li><li>For valaciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>]:<ul><li>If eGFR is 30–50 mL/minute/1.73 m<sup>2</sup>, reduce the dosage to 1000 mg every twelve hours.</li><li>If eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, reduce the dosage to 1000 mg once a day.</li><li>If eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, reduce the dosage to 500 mg once a day.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 2ef6e44a-dacb-4ff8-b942-a6b9010a327f --><!-- end item 3ed44b8d-923b-4c87-a350-a6b9010a2fe9 -->","subChapters":[]},{"id":"65440bb5-0258-5eaf-abc6-93df566b74db","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 92d72ab6-7ba6-4c00-9bf0-9b39a72f7a00 --><h3>What are the contraindications and cautions for oral aciclovir, famciclovir, and valaciclovir?</h3><!-- end field 92d72ab6-7ba6-4c00-9bf0-9b39a72f7a00 -->","summary":"","htmlStringContent":"<!-- begin item bd380926-6432-49f5-87c7-b288dc47e6e1 --><!-- begin field ef6f36ea-d61a-47e6-876f-c83f76fc10a5 --><ul><li><strong>Prescribe aciclovir, famciclovir, or valaciclovir with caution in:</strong><ul><li>People with renal impairment and in the elderly (as elderly people are likely to have reduced renal function and are at risk of neurological reactions) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>].<ul><li>In a person with renal impairment, reduce the dose of the antiviral drug depending on the level of renal impairment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/shingles/prescribing-information/antiviral-drugs/#recommended-dosage\">Recommended dosage</a> for more information.</li><li>Consider the need for a dose reduction in elderly people.</li><li>Advise the person to maintain adequate hydration, especially if they are receiving high doses [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li></ul></li><li><strong>In people with hepatic impairment:</strong><ul><li>The manufacturer of famciclovir advises that the efficacy may be decreased in severe impairment (risk of impaired conversion to active metabolite) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>].</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field ef6f36ea-d61a-47e6-876f-c83f76fc10a5 --><!-- end item bd380926-6432-49f5-87c7-b288dc47e6e1 -->","subChapters":[]},{"id":"259c681e-7533-549d-b4dc-4766776c2c6e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9791b2d5-6200-47b8-8f73-d1af9991f535 --><h3>What are the adverse effects of oral aciclovir, famciclovir, and valaciclovir?</h3><!-- end field 9791b2d5-6200-47b8-8f73-d1af9991f535 -->","summary":"","htmlStringContent":"<!-- begin item aeccb543-d21b-4c23-b362-773b70daf6bf --><!-- begin field 926aba22-687c-4af0-a7a9-1e2f19a1d0bd --><ul><li><strong>Aciclovir</strong><ul><li>Aciclovir is generally well tolerated. However, it may cause gastrointestinal adverse effects, such as nausea, vomiting, diarrhoea, and abdominal pain. Headache, dizziness, fever, fatigue, and skin rashes (including photosensitivity and urticaria) have also been commonly reported.</li><li>Other adverse effects of oral aciclovir include:<ul><li>Rare or very rare — agitation, anaemia, angioedema, ataxia, coma, confusion, drowsiness, dysarthria, dyspnoea, encephalopathy, hallucination, hepatic disorders, leucopenia, psychosis, renal impairment, renal pain, seizure, thrombocytopenia, and tremor. </li><li>Frequency not known — alopecia and crystalluria.</li></ul></li></ul></li><li><strong>Famciclovir</strong><ul><li>The most common adverse effects of famciclovir are headache, dizziness, gastrointestinal effects (such as nausea and vomiting, abdominal pain, and diarrhoea), skin disorders (such as rashes and itching), and abnormal liver function tests.</li><li>Other adverse effects of oral famciclovir include:<ul><li>Uncommon — angioedema, confusional state (predominantly in the elderly), somnolence (predominantly in the elderly), and urticaria.</li><li>Rare — thrombocytopenia, hallucinations, palpitations, and cholestatic jaundice.</li><li>Frequency not known — anaphylactic shock, anaphylactic reaction, seizure, serious skin reactions (for example erythema multiforme, Stevens- Johnson Syndrome, and toxic epidermal necrolysis) and  hypersensitivity vasculitis.</li></ul></li></ul></li><li><strong>Valaciclovir</strong><ul><li>The most common adverse effects of valaciclovir are headache, dizziness, gastrointestinal effects (such as nausea, vomiting, and diarrhoea), rashes (including photosensitivity), and itching.</li><li>Other adverse effects of oral valaciclovir include:<ul><li>Uncommon — abdominal discomfort, agitation, confusion, decreased consciousness, dyspnoea, hallucinations, haematuria (often associated with other renal events), leucopenia (mainly reported in immunocompromised people), renal pain, reversible increases in liver function tests (for example bilirubin, liver enzyme), thrombocytopenia, tremor, and urticaria.</li><li>Rare or very rare — acute renal failure (especially in elderly people or in people with renal impairment receiving higher than the recommended doses), anaphylaxis, angioedema, ataxia, coma, convulsions, delirium, dysarthria, encephalopathy, increased urea and creatinine levels, renal impairment, and psychotic symptoms. </li></ul></li><li>Neurological disorders, sometimes severe, may be linked to encephalopathy and include confusion, agitation, convulsions, hallucinations, and coma. These events are generally reversible and usually seen in elderly people and people with renal impairment.</li><li>There have been reports of renal insufficiency, microangiopathic haemolytic anaemia, and thrombocytopenia (sometimes in combination) in severely immunocompromised adults, particularly those with advanced HIV disease, receiving high doses (8000 mg daily) of valaciclovir for prolonged periods in clinical trials. These findings have also been observed in people not treated with valaciclovir who have the same underlying or concurrent conditions.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field 926aba22-687c-4af0-a7a9-1e2f19a1d0bd --><!-- end item aeccb543-d21b-4c23-b362-773b70daf6bf -->","subChapters":[]},{"id":"be1d3bdb-83d6-599e-9fb1-5a311b4113b8","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0db57821-1ec4-49bc-a872-449841efa3f1 --><h3>What are the key drug interactions with oral aciclovir, famciclovir, and valaciclovir?</h3><!-- end field 0db57821-1ec4-49bc-a872-449841efa3f1 -->","summary":"","htmlStringContent":"<!-- begin item ddad9772-b312-48fa-a452-428cb936f2a4 --><!-- begin field 44e44690-1a06-4581-b28e-7995983cdaa7 --><ul><li><strong>Aciclovir and valaciclovir </strong><ul><li>Aminophylline and theophylline — aciclovir and valaciclovir may increase the plasma concentration of aminophylline and theophylline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>]. <ul><li>The manufacturer of aciclovir advises to monitor and adjust dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>].</li><li>The manufacturer of valaciclovir makes no recommendations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li><li>See the <a data-hyperlink-id=\"f3b2122f-29d5-47d2-a803-a98f0175002a\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"29896935-0e7f-4dfc-a29f-a98f01750050\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF) for a complete list of possible drug interactions with aciclovir and valaciclovir.</li></ul></li><li><strong>Famciclovir</strong> — there are no clinically significant interactions with famciclovir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/shingles/references/\">ABPI, 2018b</a>].</li></ul><!-- end field 44e44690-1a06-4581-b28e-7995983cdaa7 --><!-- end item ddad9772-b312-48fa-a452-428cb936f2a4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}